Alternative Models in Drug Discovery and Development Part II: In Vivo Nonmammalian and Exploratory/Experimental Human Models

In Vivo Models for Drug Discovery

Volumn , Issue , 2014, Pages 59-90

  Romero, Luz ^a   Vela, José Miguel ^a  

^a ESTEVE   (Spain)

Author keywords

Caenorhabditis elegans; Drosophila; Drug discovery; Experimental human models; High throughput screening; Human diseases; Microdosing; Zebrafish

Indexed keywords

EID: 84926975538     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527679348.ch03     Document Type: Chapter

References (119)

1. Zon, L.I. and Peterson, R.T. (2005) In vivo drug discovery in the zebrafish. Nature Reviews. Drug Discovery, 4 (1), 35-44.
2. Lieschke, G.J. and Currie, P.D. (2007) Animal models of human disease:zebrafish swim into view. Nature Reviews. Genetics, 8 (5), 353-367.
3. Gibert, Y., Trengove, M.C., and Ward, A.C. (2013) Zebrafish as a genetic model in preclinical drug testing and screening. Current Medicinal Chemistry, 20 (19), 2458-2466.
4. Taylor, K.L., Grant, N.J., Temperley, N.D., and Patton, E.E. (2010) Small molecule screening in zebrafish: an in vivo approach to identifying new chemical tools and drug leads. Cell Communication and Signaling, 8, 11.
5. Peterson, R.T. and Fishman, M.C. (2011) Designing zebrafish chemical screens. Methods in Cell Biology, 105, 525-541.
6. Chakraborty, C., Hsu, C.H.,Wen, Z.H., Lin, C.S., and Agoramoorthy, G. (2009) Zebrafish: a complete animal model for in vivo drug discovery and development. Current Drug Metabolism, 10 (2), 116-124.
7. Delvecchio, C., Tiefenbach, J., and Krause, H.M. (2011) The zebrafish: a powerful platform for in vivo, HTS drug discovery. Assay and Drug Development Technologies, 9 (4), 354-361.
8. Rubinstein, A.L. (2006) Zebrafish assays for drug toxicity screening. Expert Opinion on Drug Metabolism and Toxicology, 2 (2), 231-240.
9. Barros, T.P., Alderton,W.K., Reynolds, H. M., Roach, A.G., and Berghmans, S. (2008) Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. British Journal of Pharmacology, 154 (7), 1400-1413.
10. McGrath, P. and Li, C.Q. (2008) Zebrafish:a predictive model for assessing druginduced toxicity. Drug Discovery Today, 13 (9-10), 394-401.
11. Sipes, N.S., Padilla, S., and Knudsen, T.B. (2011) Zebrafish: as an integrative model for twenty-first century toxicity testing. Birth Defects Research Part C: Embryo Today, 93 (3), 256-267.
12. Chico, T.J., Ingham, P.W., and Crossman, D.C. (2008) Modeling cardiovascular disease in the zebrafish. Trends in Cardiovascular Medicine, 18 (4), 150-155.
13. He, J.H., Guo, S.Y., Zhu, F., Zhu, J.J., Chen, Y.X., Huang, C.J., Gao, J.M., Dong, Q.X., Xuan, Y.X., and Li, C.Q. (2013) A zebrafish phenotypic assay for assessing drug-induced hepatotoxicity. Journal of Pharmacological and Toxicological Methods, 67 (1), 25-32.
14. Selderslaghs, I.W., Hooyberghs, J., Blust, R., and Witters, H.E. (2013) Assessment of the developmental neurotoxicity of compounds by measuring locomotor activity in zebrafish embryos and larvae. Neurotoxicology and Teratology, 37, 44-56.
15. Mirat, O., Sternberg, J.R., Severi, K.E., and Wyart, C. (2013) ZebraZoom: an automated program for high-throughput behavioral analysis and categorization. Frontiers in Neural Circuits, 7, 107.
16. Ducharme, N.A., Peterson, L.E., Benfenati, E., Reif, D., McCollum, C.W., Gustafsson, J.A., and Bondesson, M. (2013) Metaanalysis of toxicity and teratogenicity of 133 chemicals from zebrafish developmental toxicity studies. Reproductive Toxicology (Elmsford, NY), 41, 98-108.
17. McGrath, P. and Seng, W.L. (2013) Use of zebrafish apoptosis assays for preclinical drug discovery. Expert Opinion on Drug Discovery, 8 (10), 1191-1202.
18. Collier, A.D. and Echevarria, D.J. (2013) The utility of the zebrafish model in conditioned place preference to assess the rewarding effects of drugs. Behavioural Pharmacology, 24 (5-6), 375-383.
19. Neelkantan, N., Mikhaylova, A., Stewart, A.M., Arnold, R., Gjeloshi, V., Kondaveeti, D., Poudel, M.K., and Kalueff, A.V. (2013) Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds. ACS Chemical Neuroscience, 4 (8), 1137-1150.
20. Kawahara, G. and Kunkel, L.M. (2013) Zebrafish based small molecule screens for novel DMD drugs. Drug Discovery Today: Technologies, 10 (1), e91-e96.
21. Jung, D.W., Oh, E.S., Park, S.H., Chang, Y.T., Kim, C.H., Choi, S.Y., and Williams, D.R. (2012) A novel zebrafish human tumor xenograft model validated for anti-cancer drug screening. Molecular BioSystems, 8 (7), 1930-1939.
22. Li, Y., Huang,W., Huang, S., Du, J., and Huang, C. (2012) Screening of anti-cancer agent using zebrafish: comparison with the MTTassay. Biochemical and Biophysical Research Communications, 422 (1), 85-90.
23. Terriente, J. and Pujades, C. (2013) Use of zebrafish embryos for small molecule screening related to cancer. Developmental Dynamics, 242 (2), 97-107.
24. Stewart, A.M., Cachat, J., Gaikwad, S., Robinson, K.S., Gebhardt, M., and Kalueff, A.V. (2013) Perspectives on experimental models of serotonin syndrome in zebrafish. Neurochemistry International, 62 (6), 893-902.
25. Mahmood, F., Mozere, M., Zdebik, A.A., Stanescu, H.C., Tobin, J., Beales, P.L., Kleta, R., Bockenhauer, D., and Russell, C. (2013) Generation and validation of a zebrafish model of EAST (epilepsy, ataxia, sensorineural deafness and tubulopathy) syndrome. Disease Models & Mechanisms, 6 (3), 652-660.
26. Stewart, A.M. and Kalueff, A.V. (2012) The developing utility of zebrafish models for cognitive enhancers research. Current Neuropharmacology, 10 (3), 263-271.
27. Ellis, L.D. and Soanes, K.H. (2012) A larval zebrafish model of bipolar disorder as a screening platform for neuro-therapeutics. Behavioural Brain Research, 233 (2), 450-457.
28. Stewart, A.M., Desmond, D., Kyzar, E., Gaikwad, S., Roth, A., Riehl, R., Collins, C., Monnig, L., Green, J., and Kalueff, A.V. (2012) Perspectives of zebrafish models of epilepsy: what, how and where next? Brain Research Bulletin, 87 (2-3), 135-143.
29. Shimada, Y., Hirano, M., Nishimura, Y., and Tanaka, T. (2012) A high-throughput fluorescence-based assay system for appetite-regulating gene and drug screening. PLoS One, 7 (12), e52549.
30. Wittmann, C., Reischl, M., Shah, A.H., Mikut, R., Liebel, U., and Grabher, C. (2012) Facilitating drug discovery: an automated high-content inflammation assay in zebrafish. Journal of Visualized Experiments, 16 (65), e4203.
31. Pfriem, A., Pylatiuk, C., Alshut, R., Ziegener, B., Schulz, S., and Bretthauer, G. (2012) A modular, low-cost robot for zebrafish handling. Conference Proceedings of the IEEE Engineering in Medicine & Biology Society, pp. 980-983.
32. Pardo-Martin, C., Allalou, A., Medina, J., Eimon, P.M., Wählby, C., and Fatih Yanik, M. (2013) High-throughput hyperdimensional vertebrate phenotyping. Nature Communications, 4, 1467.
33. Rubinstein, A.L. (2003) Zebrafish: from disease modeling to drug discovery. Current Opinion in Drug Discovery & Development, 6 (2), 218-223.
34. Miscevic, F., Rotstein, O., and Wen, X.Y. (2012) Advances in zebrafish high content and high throughput technologies. Combinatorial Chemistry & High Throughput Screening, 15 (7), 515-521.
35. Gibert, Y., Trengove, M.C., and Ward, A.C. (2013) Zebrafish as a genetic model in pre-clinical drug testing and screening. Current Medicinal Chemistry, 20 (19), 2458-2466.
36. Lessman, C.A. (2011) The developing zebrafish (Danio rerio): a vertebrate model for high-throughput screening of chemical libraries. Birth Defects Research Part C:Embryo Today, 93 (3), 268-280.
37. Carroll, P.M., Dougherty, B., Ross-Macdonald, P., Browman, K., and FitzGerald, K. (2003) Model systems in drug discovery: chemical genetics meets genomics. Pharmacology & Therapeutics, 99 (2), 183-220.
38. Perrimon, N., Friedman, A., Mathey-Prevot, B., and Eggert, U.S. (2007) Drugtarget identification in Drosophila cells:combining high-throughout RNAi and small-molecule screens. Drug Discovery Today, 12 (1-2), 28-33.
39. Nichols, C.D., Becnel, J., and Pandey, U.B. (2012) Methods to assay Drosophila behavior. Journal of Visualized Experiments, 61, e3795.
40. Gladstone, M. and Su, T.T. (2011) Chemical genetics and drug screening in Drosophila cancer models. Journal of Genetics and Genomics, 38 (10), 497-504.
41. Rudrapatna, V.A., Cagan, R.L., and Das, T.K. (2012) Drosophila cancer models. Developmental Dynamics, 241 (1), 107-118.
42. Willoughby, L.F., Schlosser, T., Manning, S.A., Parisot, J.P., Street, I.P., Richardson, H.E., Humbert, P.O., and Brumby, A.M. (2013) An in vivo large-scale chemical screening platform using Drosophila for anti-cancer drug discovery. Disease Models & Mechanisms, 6 (2), 521-529.
43. Teleman, A.A., Ratzenböck, I., and Oldham, S. (2012) Drosophila: a model for understanding obesity and diabetic complications. Experimental and Clinical Endocrinology & Diabetes, 120 (4), 184-185.
44. Skorupa, D.A., Dervisefendic, A., Zwiener, J., and Pletcher, S.D. (2008) Dietary composition specifies consumption, obesity, and lifespan in Drosophila melanogaster. Aging Cell, 7 (4), 478-490.
45. Musselman, L.P., Fink, J.L., Narzinski, K., Ramachandran, P.V., Hathiramani, S.S., Cagan, R.L., and Baranski, T.J. (2011) A high-sugar diet produces obesity and insulin resistance in wild-type Drosophila. Disease Models & Mechanisms, 4 (6), 842-849.
46. Gasque, G., Conway, S., Huang, J., Rao, Y., and Vosshall, L.B. (2013) Small molecule drug screening in Drosophila identifies the 5HT2A receptor as a feeding modulation target. Scientific Reports, 3, srep02120.
47. Milinkeviciute, G., Gentile, C., and Neely, G.G. (2012) Drosophila as a tool for studying the conserved genetics of pain. Clinical Genetics, 82 (4), 359-366.
48. Tracey, W.D., Jr., Wilson, R.I., Laurent, G., and Benzer, S. (2003) painless, a Drosophila gene essential for nociception. Cell, 113 (2), 261-273.
49. Neely, G.G., Hess, A., Costigan, M., Keene, A.C., Goulas, S., Langeslag, M., Griffin, R.S., Belfer, I., Dai, F., Smith, S.B., Diatchenko, L., Gupta, V., Xia, C.P., Amann, S., Kreitz, S., Heindl-Erdmann, C., Wolz, S., Ly, C.V., Arora, S., Sarangi, R., Dan, D., Novatchkova, M., Rosenzweig, M., Gibson, D.G., Truong, D., Schramek, D., Zoranovic, T., Cronin, S.J., Angjeli, B., Brune, K., Dietzl, G., Maixner,W., Meixner, A., Thomas,W., Pospisilik, J.A., Alenius, M., Kress, M., Subramaniam, S., Garrity, P.A., Bellen, H.J.,Woolf, C.J., and Penninger, J.M. (2010) A genome-wide Drosophila screen for heat nociception identifies α2δ3 as an evolutionarily conserved pain gene. Cell, 143 (4), 628-638.
50. Neely, G.G., Keene, A.C., Duchek, P., Chang, E.C.,Wang, Q.P., Aksoy, Y.A., Rosenzweig, M., Costigan, M.,Woolf, C.J., Garrity, P.A., and Penninger, J.M. (2011) TrpA1 regulates thermal nociception in Drosophila. PLoS One, 6 (8), e24343.
51. Chattopadhyay, A., Gilstrap, A.V., and Galko, M.J. (2012) Local and global methods of assessing thermal nociception in Drosophila larvae. Journal of Visualized Experiments, 63, e3837.
52. Sulkowski, M.J., Kurosawa, M.S., and Cox, D.N. (2011) Growing pains: development of the larval nocifensive response in Drosophila. The Biological Bulletin, 221 (3), 300-306.
53. Babcock, D.T., Shi, S., Jo, J., Shaw, M., Gutstein, H.B., and Galko, M.J. (2011) Hedgehog signaling regulates nociceptive sensitization. Current Biology, 21 (18), 1525-1533.
54. Manev, H. and Dimitrijevic, N. (2005) Fruit flies for anti-pain drug discovery. Life Sciences, 76 (21), 2403-2407.
55. van Alphen, B. and van Swinderen, B. (2013) Drosophila strategies to study psychiatric disorders. Brain Research Bulletin, 92, 1-11.
56. Siller, S.S. and Broadie, K. (2011) Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. Disease Models & Mechanisms, 4 (5), 673-685.
57. Schleyer, M., Saumweber, T., Nahrendorf, W., Fischer, B., von Alpen, D., Pauls, D., Thum, A., and Gerber, B. (2011) A behavior-based circuit model of how outcome expectations organize learned behavior in larval Drosophila. Learning & Memory, 18 (10), 639-653.
58. Kahsai, L. and Zars, T. (2011) Learning and memory in Drosophila: behavior, genetics, and neural systems. International Review of Neurobiology, 99, 139-167.
59. Iijima, K. and Iijima-Ando, K. (2008) Drosophila models of Alzheimer's amyloidosis: the challenge of dissecting the complex mechanisms of toxicity of amyloid-beta 42. Journal of Alzheimer's Disease, 15 (4), 523-540.
60. Wang, L., Chiang, H.C.,Wu,W., Liang, B., Xie, Z., Yao, X., Ma,W., Du, S., and Zhong, Y. (2012) Epidermal growth factor receptor is a preferred target for treating amyloidb- induced memory loss. Proceedings of the National Academy of Sciences of the United States of America, 109 (41), 16743-16748.
61. Khan, S., Jyoti, S., Naz, F., Shakya, B., Rahul, Afzal, M., and Siddique, Y.H. (2012) Effect of L-ascorbic acid on the climbing ability and protein levels in the brain of Drosophila model of Parkinson's disease. The International Journal of Neuroscience, 122 (12), 704-709.
62. Shaltiel-Karyo, R., Davidi, D., Frenkel-Pinter, M., Ovadia, M., Segal, D., and Gazit, E. (2012) Differential inhibition of a-synuclein oligomeric and fibrillar assembly in Parkinson's disease model by cinnamon extract. Biochimica et Biophysica Acta, 1820 (10), 1628-1635.
63. Campesan, S., Green, E.W., Breda, C., Sathyasaikumar, K.V., Muchowski, P.J., Schwarcz, R., Kyriacou, C.P., and Giorgini, F. (2011) The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Current Biology, 21 (11), 961-966.
64. Kaun, K.R., Devineni, A.V., and Heberlein, U. (2012) Drosophila melanogaster as a model to study drug addiction. Human Genetics, 131 (6), 959-975.
65. Heberlein, U., Tsai, L.T., Kapfhamer, D., and Lasek, A.W. (2009) Drosophila, a genetic model system to study cocainerelated behaviors: a review with focus on LIM-only proteins. Neuropharmacology, 56 (Suppl. 1), 97-106.
66. Rodan, A.R. and Rothenfluh, A. (2010) The genetics of behavioral alcohol responses in Drosophila. International Review of Neurobiology, 91, 25-51.
67. Robinson, B.G., Khurana, S., and Atkinson, N.S. (2013) Drosophila larvae as a model to study physiological alcohol dependence. Communicative & Integrative Biology, 6 (2), e23501.
68. Lionakis, M.S. and Kontoyiannis, D.P. (2012) Drosophila melanogaster as a model organism for invasive aspergillosis. Methods in Molecular Biology, 845, 455-468.
69. Oh, C.T., Moon, C., Choi, T.H., Kim, B.S., and Jang, J. (2012) Mycobacterium marinum infection in Drosophila melanogaster for antimycobacterial activity assessment. The Journal of Antimicrobial Chemotherapy, 68 (3), 601-609.
70. Arvanitis, M., Glavis-Bloom, J., and Mylonakis, E. (2013) Invertebrate models of fungal infection. Biochimica et Biophysica Acta, 1832 (9), 1378-1383.
71. Tzelepis, I., Kapsetaki, S.E., Panayidou, S., and Apidianakis, Y. (2013) Drosophila melanogaster: a first step and a steppingstone to anti-infectives. Current Opinion in Pharmacology, 13 (5), 763-768.
72. Chamilos, G., Samonis, G., and Kontoyiannis, D.P. (2011) Drosophila melanogaster as a model host for the study of microbial pathogenicity and the discovery of novel antimicrobial compounds. Current Pharmaceutical Design, 17 (13), 1246-1253.
73. Tickoo, S. and Russell, S. (2002) Drosophila melanogaster as a model system for drug discovery and pathway screening. Current Opinion in Pharmacology, 2 (5), 555-560.
74. Giacomotto, J. and Ségalat, L. (2010) Highthroughput screening and small animal models, where are we? British Journal of Pharmacology, 160 (2), 204-216.
75. Pandey, U.B. and Nichols, C.D. (2011) Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacological Reviews, 63 (2), 411-436.
76. C. elegans Sequencing Consortium (1998) Genome sequence of the nematode C. elegans: a platform for investigating biology. Science, 282 (5396), 2012-2018.
77. Choy, R.K. and Thomas, J.H. (1999) Fluoxetine-resistant mutants in C. elegans define a novel family of transmembrane proteins. Molecular Cell, 4 (2), 143-152.
78. Siddiqui, S.S., Loganathan, S., Krishnaswamy, S., Faoro, L., Jagadeeswaran, R., and Salgia, R. (2008) C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biology & Therapy, 7 (6), 856-863.
79. Olsen, A., Vantipalli, M.C., and Lithgow, G.J. (2006) Using Caenorhabditis elegans as a model for aging and age-related diseases. Annals of the New York Academy of Sciences, 1067, 120-128.
80. Leung, M.C., Williams, P.L., Benedetto, A., Au, C., Helmcke, K.J., Aschner, M., and Meyer, J.N. (2008) Caenorhabditis elegans:an emerging model in biomedical and environmental toxicology. Toxicological Sciences, 106 (1), 5-28.
81. Squiban, B. and Kurz, C.L. (2011) C. elegans: an all in one model for antimicrobial drug discovery. Current Drug Targets, 12 (7), 967- 977.
82. McColl, G., Roberts, B.R., Pukala, T.L., Kenche, V.B., Roberts, C.M., Link, C.D., Ryan, T.M., Masters, C.L., Barnham, K.J., Bush, A.I., and Cherny, R.A. (2012) Utility of an improved model of amyloid-beta (Aβ1- 42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease. Molecular Neurodegeneration, 7, 57.
83. Lublin, A. and Link, C. (2013) Alzheimer's disease drug discovery: in-vivo screening using C. elegans as a model for β-amyloid peptide-induced toxicity. Drug Discovery Today: Technologies, 10 (1), e115-e119.
84. Artal-Sanz, M., de Jong, L., and Tavernarakis, N. (2006) Caenorhabditis elegans: a versatile platform for drug discovery. Journal of Biotechnology, 1 (12), 1405-1418.
85. Ségalat, L. (2006) Drug discovery: here comes the worm. ACS Chemical Biology, 1 (5), 277-278.
86. Silverman, G.A., Luke, C.J., Bhatia, S.R., Long, O.S., Vetica, A.C., Perlmutter, D.H., and Pak, S.C. (2009) Modeling molecular and cellular aspects of human disease using the nematode Caenorhabditis elegans. Pediatric Research, 65 (1), 10 -18.
87. Leung, C.K., Wang, Y., Malany, S., Deonarine, A., Nguyen, K., Vasile, S., and Choe, K.P. (2013) An ultra highthroughput, whole-animal screen for small molecule modulators of a specific genetic pathway in Caenorhabditis elegans. PLoS One, 8 (4), e62166.
88. Coleman, R.A. (2009) Drug discovery and development tomorrow: changing the mindset. Alternatives to Laboratory Animals, 37 (Suppl. 1), 1 -4.
89. Hillier, C. and Bunton, D. (2009) Could fresh human tissues play a key role in drug development? Alternatives to Laboratory Animals, 37 (Suppl. 1), 5-10.
90. Murray, R.M., Paparelli, A., Morrison, P.D., Marconi, A., and Di Forti, M. (2013) What can we learn about schizophrenia from studying the human model, druginduced psychosis? American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 162 (7), 661-670.
91. Garner, R.C. (2000) Accelerator mass spectrometry in pharmaceutical research and development: a new ultrasensitive analytical method for isotope measurement. Current Drug Metabolism, 1 (2), 205-213.
92. Lappin, G. and Garner, R.C. (2003) Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nature Reviews. Drug Discovery, 2 (3), 233-240.
93. Combes, R.D., Berridge, T., Connelly, J., Eve, M.D., Garner, R.C., Toon, S., and Wilcox, P. (2003) Early microdose drug studies in human volunteers can minimise animal testing: proceedings of a workshop organised by Volunteers in Research and Testing. European Journal of Pharmaceutical Sciences, 19 (1), 1-11.
94. European Medicines Agency (2004) Position Paper on Non-Clinical Safety Studies to Support Clinical Trials with a Single Microdose. CPMP/SWP/2599/02/ Rev1. Superseded by ICH M3(R2). Available at http://www.ema.europa.eu/ ema/index.jsp?curl1/4pages/regulation/ general/general_content_000400.jsp, http://www.ema.europa.eu/docs/en_GB/ document_library/Scientific_guideline/ 2009/09/WC500002720.pdf (accessed October 27, 2013).
95. Food and Drug Administration (2006) Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies. Available at http://www.fda.gov/ downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ UCM078933.pdf (accessed October 27, 2013).
96. Japanese Ministry of Health, Labor and Welfare (2008) Guidance for the Performing of Microdose Clinical Trials. PFSB/ELD Notification No. 0603001 of the Evaluating and Licensing Division. Ministry of Health, Labor and Welfare, Pharmaceutical and Medical Safety Bureau, Tokyo, Japan.
97. European Medicines Agency (2009) ICH Topic M3: Note for Guidance on Non-Clinical Safety Pharmacology Studies for Human Pharmaceuticals. EMA/CPMP/ ICH/286/1995. Available at http://www. ema.europa.eu/docs/en_GB/ document_library/Scientific_guideline/ 2009/09/WC500002720.pdf (accessed October 27, 2013).
98. Lappin, G. and Garner, R.C. (2008) The utility of microdosing over the past 5 years. Expert Opinion on Drug Metabolism and Toxicology, 4 (12), 1499-1506.
99. Lappin, G., Noveck, R., and Burt, T. (2013) Microdosing and drug development: past, present and future. Expert Opinion on Drug Metabolism and Toxicology, 9 (7), 817-834.
100. Lappin, G. (2010) Microdosing: current and the future. Bioanalysis, 2 (3), 509-517.
101. Murgo, A.J., Kummar, S., Rubinstein, L., Gutierrez, M., Collins, J., Kinders, R., Parchment, R.E., Ji, J., Steinberg, S.M., Yang, S.X., Hollingshead, M., Chen, A., Helman, L., Wiltrout, R., Tomaszewski, J. E., and Doroshow, J.H. (2008) Designing phase 0 cancer clinical trials. Clinical Cancer Research, 14 (12), 3675-3682.
102. Gupta, U.C., Bhatia, S., Garg, A., Sharma, A., and Choudhary, V. (2011) Phase 0 clinical trials in oncology new drug development. Perspectives in Clinical Research, 2 (1), 13-22.
103. Marchetti, S. and Schellens, J.H. (2007) The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. British Journal of Cancer, 97 (5), 577-581.
104. Robinson,W.T. (2008) Innovative early development regulatory approaches:expIND, expCTA, microdosing. Clinical Pharmacology and Therapeutics, 83 (2), 358-360.
105. Eliopoulos, H., Giranda, V., Carr, R., Tiehen, R., Leahy, T., and Gordon, G. (2008) Phase 0 trials: an industry perspective. Clinical Cancer Research, 14 (12), 3683-3688.
106. Rawlins, M.D. (2004) Cutting the cost of drug development? Nature Reviews. Drug Discovery, 3 (4), 360-364.
107. Lappin, G., Kuhnz,W., Jochemsen, R., Kneer, J., Chaudhary, A., Oosterhuis, B., Drijfhout, W.J., Rowland, M., and Garner, R.C. (2006) Use of microdosing to predict pharmacokinetics at the therapeutic dose:experience with 5 drugs. Clinical Pharmacology and Therapeutics, 80 (3), 203-215.
108. Oosterhuis, B. (2010) Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development. Bioanalysis, 2 (3), 377-379.
109. Chauhan, B.N., Modi, C.M., Mody, S.K., Patel, H.B., Dudhatra, G.B., and Kamani, D.R. (2012) Pharmaco-economics of microdosing clinical trials in drug development process. International Journal of Analytical, Pharmaceutical and Biomedical Sciences, 1 (3), 25-36.
110. Yamane, N., Igarashi, A., Kusama, M., Maeda, K., Ikeda, T., and Sugiyama, Y. (2013) Cost-effectiveness analysis of microdose clinical trials in drug development. Drug Metabolism and Pharmacokinetics, 28 (3), 187-195.
111. Sheiner, L.B. (1997) Learning versus confirming in clinical drug development. Clinical Pharmacology and Therapeutics, 61 (3), 275-291.
112. Patterson, S.D. (2010) Experiences with learning and confirming in drug and biological development. Clinical Pharmacology and Therapeutics, 88 (2), 161-163.
113. Wong, D.F., Potter, W.Z., and Brasic, J.R. (2002) Proof of concept: functional models for drug development in humans, in Neuropsychopharmacology: The Fifth Generation of Progress (eds K.L. Davis, D. Charney, J.T. Coyle, and N. Charles), Lippincott Williams & Wilkins, Philadelphia, PA, pp. 457-473.
114. Arendt-Nielsen, L. and Sumikura, H. (2002) From pain research to pain treatment: role of human pain models. Journal of Nippon Medical School, 69 (6), 514-524.
115. Wise, R.G. and Tracey, I. (2006) The role of fMRI in drug discovery. Journal of Magnetic Resonance Imaging, 23 (6), 862-876.
116. Arendt-Nielsen, L., Curatolo, M., and Drewes, A. (2007) Human experimental pain models in drug development:translational pain research. Current Opinion in Investigational Drugs, 8 (1), 41-53.
117. Olesen, A.E., Andresen, T., Staahl, C., and Drewes, A.M. (2012) Human experimental pain models for assessing the therapeutic efficacy of analgesic drugs. Pharmacological Reviews, 64 (3), 722-779.
118. Reddy, K.S., Naidu, M.U., Rani, P.U., and Rao, T.R. (2012) Human experimental pain models: a review of standardized methods in drug development. Journal of Research in Medical Sciences, 17 (6), 587-595.
119. Oertel, B.G. and Lötsch, J. (2013) Clinical pharmacology of analgesics assessed with human experimental pain models:bridging basic and clinical research. British Journal of Pharmacology, 168 (3), 534-553.